Preferred Label : Erfonrilimab;
NCIt synonyms : Anti-PD-L1/Anti-CTLA-4 Bispecific Antibody KN046; Anti-PD-L1 x CTLA-4 Bispecific Antibody KN046; Anti-PD-L1/CTLA-4 Bispecific Antibody KN046;
NCIt definition : A bispecific monoclonal antibody directed against both the immunosuppressive ligand,
programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune
checkpoint inhibitory and antineoplastic activities. Upon administration, erfonrilimab
targets and binds to both PD-L1 expressed on tumor cells and CTLA-4 expressed on T-cells.
This prevents the binding of PD-L1 to its receptor, programmed cell death protein
1 (PD-1, CD279), and inhibits the PD-1 and CTLA-4-mediated downregulation of T-cell
activation and proliferation. This restores immune function and activates a sustained
cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-L1,
which is overexpressed in many human cancer cell types, and CTLA-4, an inhibitory
T-cell receptor, play a role in the downregulation of the immune system and tumor
evasion from host immunity.;
UNII : 9NP50O6YSA;
CAS number : 2367013-69-0;
Molecule name : KN 046; KN-046;
NCI Metathesaurus CUI : CL937174;
Origin ID : C157632;
UMLS CUI : C5554554;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
